Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review by Macey, Matthew Ryan & Raynor, Mathew C.
Medical and Surgical TreatmentModalities for Lower
Urinary Tract Symptoms in the Male Patient
Secondary to Benign Prostatic Hyperplasia: A Review
Matthew Ryan Macey, MS, MD1 Mathew C. Raynor, MD, FACS1
1Department of Urology, University of North Carolina School of
Medicine, Chapel Hill, North Carolina
Semin Intervent Radiol 2016;33:217–223
Address for correspondence Mathew C. Raynor, MD, FACS,
Department of Urology, University of North Carolina School of
Medicine, 2110 Physicians Office Building, CB 7235, 170 Manning
Drive, Chapel Hill, NC 27599-7235
(e-mail: mathew_raynor@med.unc.edu).
Objectives: Upon completion of this article, the reader will be
able to define LUTS and differentiate severity classes of LUTS;
describe conservative and medical management of LUTS
secondary to BPH; describe surgical options for management
of LUTS secondary to BPH and when to pursue these options.
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Benign Prostatic Hyperplasia—An Overview
Benign prostatic hyperplasia (BPH) refers to the proliferation
of smooth muscle and epithelial cells within the transition
zone of the prostate.1,2 “Lower urinary tract symptoms”
(LUTS) is a term used to describe bladder storage and voiding
disturbances. Storage symptoms experienced during the
storage phase of bladder filling include daytime frequency
and urgency as well as nocturia. Detrusor overactivity (DOA)
is thought to be a contributor to storage symptoms seen in
LUTS.3 Voiding symptoms experienced during the voiding
phase may include straining to urinate, intermittent urinary
stream, and weak urinary stream. BPH has been proposed to
contribute to overall LUTS via at least two routes: direct
bladder outlet obstruction (BOO) from enlarged prostatic
tissue and increased smooth muscle tone and resistance
within an enlarged prostate gland. LUTS may also be due to
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Abstract Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) is one of
the most common ailments affecting aging men. Symptoms typically associated with
BPH include weak stream, hesitancy, urgency, frequency, and nocturia. More serious
complications of BPH include urinary retention, gross hematuria, bladder calculi,
recurrent urinary tract infection, obstructive uropathy, and renal failure. Evaluation
of BPH includes a detailed history, objective assessment of urinary symptoms with
validated questionnaires, and measurement of bladder function parameters, including
uroflowmetry and postvoid residual. In general, treatment of LUTS associated with BPH
is based on the effect of the symptoms on quality of life (QOL) and include medical
therapy aimed at reducing outlet obstruction or decreasing the size of the prostate. If
medical therapy fails or is contraindicated, various surgical options exist. As the elderly
population continues to grow, the management of BPH will becomemore common and
important in maintaining patient’s QOL.
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structural or functional abnormalities of the peripheral and/
or central nervous system that provide neural control to the
lower urinary tract.
The prevalence of moderate-to-severe LUTS rises to nearly
50% by the eighth decade of life.4 Another study has estimated
that 90% of men between 45 and 80 years of age suffer some
degree of LUTS.5 The impact of LUTS and BPH on a patient’s
quality of life (QOL) can be significant. Traditionally, the primary
goal of treatment has been to alleviate bothersome LUTS that
result from prostatic enlargement. Recently, treatment has
additionally focused on the alteration of disease progression
and prevention of complications associatedwith BPHand LUTS.6
Importantly, LUTS and BPH have been shown to be associ-
ated with other comorbidities including acute urinary reten-
tion, renal insufficiency, development of gross hematuria,
bladder calculi, urinary incontinence, and recurrent urinary
tract infections (UTIs).7,8
Objective measures of a patient’s urinary symptoms in-
clude the American Urological Association-Symptom Index
(AUA-SI) and International Prostate Symptom Score (IPSS)
templates. These are short, self-administered questionnaires
used to assess the severity of three storage urinary symptoms
(urgency, frequency, and nocturia) and four voiding symp-
toms (incomplete emptying, intermittency, straining, and
weak stream). Each of the seven variables is assessed on a
0- to 5-point scale. The IPSS form also assesses the degree that
urinary symptoms affect the patient’s QOL.9,10 A total score of
0 to 7 on the IPSS correlates with mild symptoms, 8 to 19
correlates with moderate symptoms, and 20 to 35 correlates
with severe symptoms.
Lifestyle factors such as exercise, weight gain, and obesity
appear to have an impact on LUTS. Encouraging activity,
regulating fluid intake (especially in the evening), and limit-
ing bladder irritants in the diet are advisable. Bladder irritants
include excessive amounts of alcohol, caffeine, and highly
seasoned or irritative foods.11 As the prevalence of LUTS
increases with age, the overall burden and number of men
complaining of LUTSwill continue to risewith increases in life
expectancy and growth of the elderly population.
Recommendations from the American
Urological Association Guideline on BPH
• Baseline renal insufficiency appears to be no more com-
mon inmenwith BPH than inmen of the same age group in
the general population. Therefore, the routine measure-
ment of serum creatinine levels is not indicated in the
initial evaluation of men with LUTS secondary to BPH.
• If a patient’s LUTS is not significantly bothersome or if the
patient does not desire treatment, no further evaluation of
LUTS is recommended (if LUTS is considered secondary to
BPH and no other causes). Patients who have LUTS that not
bothersome are unlikely to experience significant health
problems in the future due to their condition.
• If a patient has predominant significant nocturia and is
awakened two or more times a night to void, a frequency
volume chart should be completed for 2 to 3 days. This will
show 24-hour polyuria (> 3 L urine output) or nocturnal
polyuria (when more than 33% of 24-hour urine output
occurs at night) when present.
• Patients with bothersome LUTS are advised to aim for a
total urine output of 1 L over 24 hours.
• If pharmacologic treatment is necessary for management
of a patient’s LUTS, it is recommended that the patient be
followed to assess treatment success and potential adverse
effects. If a treatment is successful and a patient is satisfied,
once yearly follow-up is satisfactory and should include a
repeat of the initial evaluation.
• α-Antagonists are the first-line medical treatment of
choice for moderate-to-severe LUTS due to BPH.
• Transurethral resection of the prostate (TURP) is still
considered the gold standard of interventional treatment,
if required.
Treatment Options for Mild Urinary Tract
Symptoms (IPSS < 8)
Watchful waiting should be employed for mild LUTS second-
ary to BPHand in patientswithmoderate or severe symptoms
that are not bothered by LUTS or do not wish to pursue
treatment. Watchful waiting includes monitoring patients for
adverse effects related to LUTS and BPH, including renal
insufficiency, acute urinary retention, and/or recurrent UTIs.
Symptom distress may be improved with weight loss,
increased exercise, decreased fluid intake (especially at bed-
time), and decreased bladder irritant intake (e.g., caffeine and
alcohol). Avoidance of decongestants (α agonists can cause
further increase in smooth muscle tone of prostate) and
antihistamines may also improve symptoms. Patients should
be examined yearly with re-evaluation of symptoms and
examination, including digital rectal exam (DRE) and prostate
specific antigen (PSA), as indicated.
Complementary and Alternative Medicines
for LUTS Secondary to BPH
The AUA Guideline on BPH does not currently recommend
phytotherapy as treatment for LUTS secondary to BPH as data
are lacking on the efficacy of these products. However, some
men may still benefit from phytotherapy. For example, β-
sitosterol is thought to be one of the ingredients in phyto-
therapy that improves BPH symptoms, although its mecha-
nism of action remains unknown. The most commonly used
alternative medicine is saw palmetto. Current available data
do not suggest that saw palmetto has a clinically meaningful
effect on LUTS secondary to BPH.12,13 Other alternatives
include African plum tree, stinging nettle (Urtica dioica),
pumpkin seed, African star grass, and rye grass pollen.
Medical Therapy for Patients withModerate-
to-Severe LUTS (IPSS  8)
α-Antagonists
α-antagonists are effective treatment for patients with both-
ersome, moderate-to-severe LUTS secondary to BPH and are
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considered first-line medical therapy in patients without a
contraindication. These medications inhibit α-1 adrenergic
receptors and lead to relaxation of the smooth muscle in the
bladder neck and prostate.With activation of these receptors,
a subsequent increase in prostatic smooth muscle tone with
urethral contraction and impaired flow of urine results.14
This mechanism is thought to be a major contributor to the
pathophysiology of LUTS secondary to BPH. α-1A receptors
are the primary subtype of α-1 receptors in the prostate.
Up to 98% of α-adrenergic receptors are associated with
stromal elements of the prostate. Therefore,α-antagonists are
thought to have the greatest influence on prostatic smooth
muscle tone.15 These medications act in a dose-dependent
manner with a concomitant improvement in urinary symp-
tom score and maximum urinary flow rate (Qmax). With
relaxation of the smooth muscle in the prostate, bladder
neck, seminal vesicles, and vas deferens, α antagonists may
cause the adverse effect of retrograde ejaculation.
Nonselective α-1 antagonists include terazosin (Hytrin
(AbbVie), Chicago, IL), doxazosin (Cardura, Pfizer, New York,
NY), and alfuzosin (Uroxatral, Covis Pharmaceuticals, Inc.,
Cary, NC). α-1A–specific antagonists include tamsulosin
(Flomax, Boehringer Ingelheim, Ridgefield, CT) and silodosin
(Rapaflo, Actavis, Inc., Piscataway, NJ). Silodosin has the
highest affinity for α-1A receptors. Improvement can occur
within a fewdays of medication initiation; however, maximal
improvement is generally established by 1 to 3 months.
α-antagonists produce a significant symptom improvement
compared with placebo. Average benefits seen with α-antag-
onist therapy include a reduction in symptom score by
6 points and an increase in Qmax by 2 to 3 mL/s. The minor
differences in efficacy noted earlier between the different
α-antagonists are not statistically or clinically significant. Side
effects include dizziness (2–14%, higher in terazosin and
immediate release doxazosin), fatigue, nasal congestion,
orthostatic hypotension, syncope, and retrograde ejaculation.
Retrograde ejaculation can occur in up to 28% of patients
treated with silodosin and 18% of patients treated with
tamsulosin. A recent publication noted a < 10% risk of retro-
grade ejaculation with tamsulosin.16
Another side effect specific to α-antagonists includes
intraoperative floppy iris syndrome as first described in
2005.17 Patients should be asked about planned cataract
surgery before initiation of α-antagonist therapy to prevent
intraoperative floppy iris syndrome. The risk of intra-
operative floppy iris syndrome is highest in those on tamsu-
losin therapy, ranging from approximately 43 to 90%.
α-antagonists should be avoided until planned cataract sur-
gery is completed as permanent visual problems can arise
when cataract surgery is not modified to account for this.
5-α-Reductase Inhibitors
5-α-Reductase inhibitors (5-ARIs) may be used to prevent the
progression of LUTS secondary to BPH and decrease the risk of
acute urinary retention and future prostate-related surgery.
5-α-reductase is an enzyme that converts testosterone to dihy-
drotestosterone, the main active androgen within the prostate.
Medication options include finasteride (Proscar, Merck, White-
house Station, NJ) and dutasteride (Avodart, GlaxSmithKline,
Research Triangle Park, NC). Finasteride inhibits type II
5-α-reductase, whereas dutasteride inhibits types I and II
5-α-reductase. The difference in activity leads to a reduction
in the serum levels of dihydrotestosteroneby approximately 70%
with finasteride compared with approximately 95% with dutas-
teride.18 However, type II 5-α-reductase is far more common
than type I in the prostate and specifically in BPH tissues, and the
reduction of DHT in prostatic tissue has been measured at
approximately 80% with finasteride and 94% with dutaster-
ide.19–21 The Proscar Long-term Efficacy and Safety Study
showed that 5-ARIs improve urinary symptoms and flow rate
mainly in men with PSA  1.4 and prostate volume >
40 mL.22–25 Therefore, the use of 5-ARIs for LUTS secondary to
BPH is often restricted to men with these characteristics.
Symptom improvementmay beginwithin severalweeks of
initiation of medication; however, it usually takes 6 to
9 months to achieve a very noticeable change in symptoms
after starting 5-ARIs. Adverse effects notedwhile taking these
medications include erectile dysfunction (ED) (< 5%),
decreased libido (< 4%), decreased volume of ejaculate
(< 3%), and gynecomastia (< 1%). These adverse effects are
reversible and uncommon after the first year of therapy.
5-ARIs decrease DHT and reduce prostate volume by 15 to
25%, increase Qmax by approximately 10%, improve symptom
score by 20 to 30% (reduction of3–4 points), and reduce the
risk of urinary retention and need for surgical BPH therapy by
50%.22–26 These medications also reduce the risk of BPH
progression and decrease total PSA levels by approximately
50% after 9 to 12 months of treatment. They can assist in the
prevention of gross hematuria or treatment of refractory
hematuria due to prostatic bleeding by suppression of vascu-
lar endothelial growth factor.27–30 Clinically insignificant
increases in serum testosterone by 10 to 20% are also noted.
Notably, these medications are less effective than α-antago-
nists in improving LUTS when used as monotherapy.
Phosphodiesterase-5 Inhibitors
Tadalafil (Cialis) is the only phosphodiesterase-5 inhibitor that
has been approved by the Food and Drug Administration for
the treatmentof LUTS related toBPH. This therapymaybe ideal
for menwith LUTS secondary to BPH and ED, as it can improve
both conditions. Daily tadalafil therapy (5 mg) significantly
improves erectile function, voiding symptoms, and QOL.
Improvement in voiding symptoms can occur within a week,
but maximal improvement may take up to 2 months. The
combination of tadalafil and an α-antagonist significantly
improves Qmax, voiding symptoms, and ED compared with
an α-antagonist alone, and combination of tadalafil with a
5-ARI improves symptom scores more than 5-ARIs alone.31–33
Combination of Medical Therapy with
α-Antagonist and 5-α-Reductase Inhibitor
The Medical Therapy of Prostate Symptoms and Combina-
tion Avodart and Tamsulosin (CombAT) trials showed that a
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combination of an α-antagonist and a 5-ARI improves
voiding symptoms and Qmax more than either agent
alone.6,16 The combination of α-antagonist and 5-ARI is
appropriate and effective for patients with LUTS associated
with prostatic enlargement with prostate volumes > 40mL
and PSA values > 1.5. Combination therapy showed a
reduced risk of acute urinary retention, need for BPH
surgery, and progression to worse voiding symptoms. It
did not reduce renal insufficiency, recurrent UTIs, or in-
continence. Approximately 80% of men will not experience
a significant worsening of voiding symptoms when the
α-antagonist is withdrawn after 6 to 9 months of combina-
tion therapy; however, the AUA Guideline on BPH states
that the optimal duration of combination therapy prior to
discontinuation of α-antagonist remains in doubt.34 Of
note, there was a significant increase noted in drug-related
adverse effects with combination therapy versus mono-
therapies noted in the CombAT trial.
Combination Medical Therapy with
α-Antagonist and Anticholinergics
Combination medical therapy with an α-antagonist and
anticholinergic can be used for coexisting BOO symptoms
and overactive bladder (OAB) symptoms. The symptoms of
OAB (urinary urgency, frequency) may not be treated
adequately with an α-antagonist alone. Addition of an
anticholinergic results in a statistically significant
improvement in voiding symptoms, QOL, urgency, frequen-
cy, and nocturia than either agent alone. Patients should be
tested for postvoid residual before start of anticholinergic
therapy to prevent acute urinary retention. Anticholinergic
therapy should not be initiated in patients with postvoid
residuals > 200 mL, Qmax < 5 mL/s, or patients with a
history of acute urinary retention requiring catheteriza-
tion. In most studies, adding an anticholinergic to an
α-antagonist did not significantly alter PVR or Qmax. Ran-
domized controlled trials have only investigated toltero-
dine as the anticholinergic agent, and the most common
adverse event was dry mouth in 7 to 24% of patients. The
rate of acute urinary retention in these patients was similar
to placebo, as was the occurrence of constipation, diarrhea,
and somnolence.35–38
Surgical Therapy for Patients with
Moderate-to-Severe LUTS Secondary to BPH
Surgical therapy is indicated for patients with moderate-
to-severe LUTS secondary to BPH who have failed medical
therapy for more than 6 months. However, medical therapy
before surgical management of patients with LUTS secondary
to BPH is not absolutely required. It is also indicated for
patients who experience refractory urinary retention, recur-
rent UTIs, refractory gross hematuria, recurrent or large
bladder stones, renal insufficiency, or hydronephrosis. The
presence of a bladder diverticulum is not an absolute indica-
tion for surgery unless associated with recurrent UTIs or
progressive bladder dysfunction.
Minimally Invasive Surgical Therapies
Minimally invasive surgical options exist for treatment of
LUTS secondary to BPH and include transurethral needle
ablation of the prostate and transurethral microwave ther-
motherapy. An in-depth description of these procedures is
beyond the scope of this review. Although significant im-
provements are noted in voiding symptoms (9- to 11-point
reduction), QOL, and Qmax (3–4mL/s), these do not match the
results seen with TURP. In general, the minimally invasive
treatment approaches mentioned lack sufficient durability of
effect when compared with TURP and therefore do not play a
greater role in management of LUTS secondary to BPH.
Transurethral Resection of the Prostate
TURP remains the gold standard and benchmark for surgical
therapy for treatment of LUTS secondary to BPH. This proce-
dure involves the resection of prostatic tissue circumferen-
tially from the bladder neck to just cephalad to the
verumontanum. The success rate of TURP is higher in patients
with preoperative Qmax < 15 mL/s (consistent with ob-
structed voiding) and men substantially bothered by urinary
symptoms. This procedure is most suitable for patients with
prostate volumes < 80 mL, due to the limitations of success-
fully performing surgery as prostate volume size increases.
Historically, monopolar technology was used to perform
TURP. The transurethral resection (TUR) syndrome was a
complication of monopolar TURP in 1% of cases secondary
to the excessive absorption of hypotonic irrigation fluid from
the prostatic vascular bed. TUR syndrome led to hyponatre-
mia, hypervolemia, hypertension, altered mental status, nau-
sea with vomiting, and visual changes. The risk of TUR
syndrome is higher when the duration of monopolar TURP
surgery is long, irrigation pressures are high, and the resec-
tion bed contains open venous sinuses.
Bipolar TURP is now available which can be used to resect,
coagulate, vaporize, and transect tissue. Bipolar technology
uses a specialized resectoscope loop that incorporates both
the active and return electrodes, which reduces the effects of
stray current flow during the procedure. Importantly, normal
saline irrigation may be used with bipolar technology, which
allows for an isotonic irrigant and thereby eliminates the risk
of TUR syndrome.
Average improvement in symptoms score demonstrates
a 15-point reduction in the IPSS along with an average
increase in Qmax of 11 mL/s. TURP should be approached
with caution in patients who have received prior prostate
cryotherapy or radiation as the risk of postoperative uri-
nary incontinence is significantly increased in these
patients. Complications associated with TURP include post-
operative bleeding requiring blood transfusion, ED, irrita-
tive voiding symptoms, bladder neck contracture,
hematuria, UTI, TUR syndrome, and identification of pros-
tate cancer in prostate specimen sent for pathology (up to
10%). The Veterans Affairs Cooperative Study found a 1%
risk of urinary incontinence, which was similar to the
incidence in the control group (watchful waiting) and an
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overall decline in sexual function identical to the control
treatment group.39
Historically, the TURP procedure was the most common
active treatment for BPH. However, potential morbidities, the
desire to shorten Foley catheter indwelling time course, and
the pressure to reduce hospital length of stay have stimulated
research into alternative procedures.
Transurethral Incision of the Prostate
Transurethral incision of the prostate (TUIP) is an effective
treatment in men with moderate-to-severe LUTS secondary
to BPH when the prostate size is less than 30 mL. This
procedure is most effective in men with smaller prostate
size associated with a “high-riding” bladder neck. TUIP is
typically an outpatient procedure involving one or two
incisions in the prostate from the bladder neck to just
cephalad to the verumontanum, which thereby reduces
constriction of the urethra. Symptomatic improvement in
the appropriately selected patient is equivalent to those
attained after TURP, showing an average of 15-point reduc-
tion in symptom score and 7mL/s improvement in Qmax.40–43
There is a significantly reduced riskof ejaculatory disturbance
compared with TURP. However, TUIP is associated with a
slightly higher rate of required secondary procedures.
Transurethral Laser Surgical Management
Transurethral laser therapies for LUTS secondary to BPH
involve the use of a laser to resect or vaporize the prostatic
tissue. The choice of approach should be based on the
patient’s presentation, anatomy, surgeon’s level of training
and experience, and risks versus benefits of the procedure.
When compared with TURP, laser therapies show a compara-
ble improvement in voiding symptoms with a lower risk of
bleeding, shorter postoperative catheterization time, and
shorter length of stay in the hospital. However, information
concerning certain outcomes including retreatment has been
limited due to short follow-up time. The AUA Guideline on
transurethral laser surgeries for LUTS secondary to BPH states
that emerging evidence suggests a possible role of trans-
urethral enucleation and laser vaporization as options for
men with very large prostates (100 g).34
Photoselective vaporization of the prostate involves the
use of potassium titanyl phosphate and/or lithium borate
lasers, referred to as “green light lasers,” as the wavelength is
in the green portion of the visible spectrum. This wavelength
is absorbed by water irrigation as well as hemoglobin and
results in a penetration depth of 0.8 mm. The procedure is
typically performed using normal saline irrigation and a
continuous flow scope. Symptom scores have improved con-
sistently in all studies with an average of approximately
14-point reduction44,45 with an improvement in Qmax of
approximately 11 mL/s.46,47
Holmium laser enucleation of the prostate (HoLEP) sepa-
rates the prostatic adenoma from the surgical capsule from
apex to base and after any median lobe has been freed from
the bladder neck. A tissue morcellator can be used to mor-
cellate tissue within the bladder allowing for shorter opera-
tive times. This procedure is typically used for larger glands
that historically would have been treated with open prosta-
tectomy. The results are generally comparable to open pros-
tatectomy, depending on the surgeon’s experience.48–50
Other HoLEP studies have shown improvements in symp-
tom scores, QOL, and Qmax that approach those after TURP
(up to 18-point reduction in symptom score with 11 mL/s
increase in Qmax).51,52 Long-term data remain lacking, and
therefore, the widespread use of HoLEP has been limited. The
procedure also requires specialized training with a learning
curve that appears to be greater than that of other surgical
interventions.
Simple Prostatectomy
Simple prostatectomy is typically reserved for menwith large
prostates (> 80 mL) or men who cannot tolerate a trans-
urethral procedure. Surgical approaches include a suprapu-
bic, retropubic, or perineal approach. The suprapubic
approach is the most common approach for patients with
very large prostate glands and is ideal for patients who
require concomitant removal of bladder stones or excision
of bladder diverticula. Minimally invasive laparoscopic and
robotic approaches to simple prostatectomy have been
described, with open simple prostatectomy typically associ-
ated with a longer hospital stay and larger loss of blood when
compared with the robotic approach. When compared with
TURP, open prostatectomy is associatedwith an increased risk
of blood loss, transfusion, and longer hospital stay. Open
prostatectomy shows an average 10-point reduction in symp-
tom scores and 14 mL/s improvement in Qmax.
Surgical Considerations
Symptoms can persist in up to 15 to 20% of men after invasive
treatment for BPH. Video urodynamics can be employed
when voiding symptoms persist after invasive treatment to
assess for obstructive voiding indices or DOA. DOA may take
as long as 1 year to resolve after surgical interventions for
BPH. The most common causes of urinary incontinence after
invasive treatment are DOA and urinary sphincteric damage
during the surgical procedure. Overall, surgery improves
symptom scores and Qmax more than any other therapies
employed for LUTS secondary to BPH.
Conclusion
LUTS secondary to BPH is an important health issue in the
aging male patient who can have significant impacts on QOL.
Mild LUTS can be treated with lifestyle factors and watchful
waiting. Moderate-to-severe LUTS can be given a trial of
medical therapy when appropriate, with α-antagonists being
the first-line medical therapy with an average 6-point reduc-
tion in symptom scores. 5-ARI therapy is useful for patients
with prostate volumes > 40mL and PSA > 1.5. Tadalafil is an
optimal therapeutic option for patients with BPH and con-
comitant ED. For patients who fail medical therapy or
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experience complications secondary to LUTS and BPH (e.g.,
acute urinary retention, recurrent UTIs, bladder calculi, renal
insufficiency), surgical intervention may be pursued. TURP is
still considered the gold standard surgical intervention for
patients with moderate-to-severe LUTS; however, there are
myriad surgical options with varying side effect profiles and
success rates. As the average life expectancy and elderly
population continue to increase, LUTS secondary to BPH
should be expected to increase in incidence. It is, therefore,
imperative to understand the medical and surgical options
available to patients for treatment of LUTS secondary to BPH.
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